Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease

Neurology

Volumn 72, Issue 1, 2009, Pages 50-55

  Squitti, R ^a,b,d   Bressi, F ^b   Pasqualetti, P ^a,c   Bonomini, C ^a   Ghidoni, R ^a   Binetti, G ^a   Cassetta, E ^a   Moffa, F ^a   Ventriglia, M ^a,b   Vernieri, F ^b   Rossini, P M ^a,b,c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d Cassino and IRCCS San Raffaele Pisana ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CERULOPLASMIN; CHOLINESTERASE INHIBITOR; COPPER; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; ORAL ANTIDIABETIC AGENT; PEROXIDE; TRANSFERRIN; ZINC;

AGE; AGED; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CERULOPLASMIN BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; COPPER BLOOD LEVEL; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IRON BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; ZINC BLOOD LEVEL; BLOOD; DISEASE COURSE; LONGITUDINAL STUDY; MENTAL HEALTH; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; PROBABILITY; PROGNOSIS; RISK FACTOR; STATISTICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; COPPER; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RISK FACTORS; STATISTICS AS TOPIC;

EID: 63849241137     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000338568.28960.3f     Document Type: Article

References (29)

1. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005;64:1040-1046.
2. Squitti R, Barbati G, Rossi L, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau. Neurology 2006;67:76-82.
3. Capo CR, Arciello M, Squitti R, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008;21:367-372.
4. Hoogenraad TU. Measuring hypercupremia in blood of patients with Alzheimer's disease is logical, but the utility of measuring free-copper has to be proven. In: Frijns CJM, Kappelle LJ, Klijn CJM, Wokke JHJ. Neurologie. Utrechts Tijdschrift voor; 2007:111-112.
5. Walshe JM. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003;40:115-121.
6. Hoogenraad TU. Monography: Wilson's disease. In: Major Problems in Neurology. Vol 30. London: W.B. Saunders; 1996.
7. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
8. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. Clin Chem 1989;35:552-554.
11. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002;59: 1153-1161.
12. Wolf PL. Ceruloplasmin: methods and clinical use. Crit Rev Clin Lab Sci 1982;17:229-245.
13. Lehmann HP, Schosinsky KH, Beeler MF. Standardization of serum ceruloplasmin concentrations in international enzyme units with o-dianisidine dihydrochloride as substrate. Clin Chem 1974;20:1564-1567.
14. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974;20: 1556-1563.
15. Squitti R, Rossini PM, Cassetta E, et al. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002;32:51-59.
16. Alberti A, Bolognini L, Macciantelli D, Carratelli M. The radical cation of N,N-Diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000;26:253-267.
17. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234: 279-293.
18. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990;75:1870-1876.
19. Higgins T. Novel chromogen for serum iron determinations. Clin Chem 1981;27:1619-1620.
20. Maffulli V, De Luca U. A new direct colorimetric method for the determination of zinc in biochemical fluids without deproteinization of the sample. European Clinical Laboratory, Biochemicals/Application Note, 1992.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
22. Scheltens P, Launer LJ, Barkhof F, et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance reliability. J Neurol 1995;242:557-560.
23. Carcaillon L, Pérès K, Péré JJ, et al. Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community. Dement Geriatr Cogn Disord 2007;23:439-445.
24. Sluimer JD, Vrenken H, Blankenstein MA, et al. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008;70:1836-1841.
25. Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood) 2007;232:323-335.
26. Chutkow JG. Evidence for uptake of nonceruloplasminic copper in the brain: effect of ionic copper and amino acids. Proc Soc Exp Biol Med 1978;158:113-116.
27. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:11065-11069.
28. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006;63:1085-1088.
29. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60: 1685-1691.